9 completed, 8 recruiting, 5 not yet recruiting, 3 active not recruiting. 9 Phase 2, 7 Not applicable, 4 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Non Muscle Invasive Bladder Cancer: new trials by email Literature Review of Non Muscle Invasive Bladder Cancer trials Research Report on Non Muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC | Not yet recruiting | Bladder Cancer Advocacy Network | 1400 | 2027-03-01 | 2026-10-26 | |
| Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients Hyperthermic Intravesical Chemotherapy (HIVEC) - Non Muscle Invasive Bladder Cancer, Bladder Cancer | Not applicable | Not yet recruiting | AC.TA. S.r.l. | 50 | 2026-10-15 | 2026-05-06 |
| The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer Definitive radiotherapy, BCG, Concurrent chemotherapy - Non Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Assiut University | 70 | 2026-10-02 | 2026-10-14 |
| Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT Toripalimab (JS001 ), Gemcitabine (GEM) - Non Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 54 | 2026-10-01 | 2026-09-08 |
| Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy - Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 120 | 2026-05-30 | 2026-10-15 |
| Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy intravesical Chemotherapy docetaxel/gemcitabine - Non Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | BLATAM | 37 | 2026-05-21 | 2026-05-28 |
| Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging Bladder Cancer, Urothelial Carcinoma (UC) | Recruiting | Oslo University Hospital | 150 | 2026-04-22 | 2026-05-22 | |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 2 | Recruiting | Lepu Biopharma Co., Ltd. | 16 | 2025-12-04 | 2026-04-23 |
| Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial Gemcitabine Submucosal Injection, Gemcitabine Intravesical Instillation - Non Muscle Invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai University of Traditional Chinese Medicine | 320 | 2025-10-01 | 2025-09-30 |
| A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing Urine biomarker -Guided without reTURBT - Non Muscle Invasive Bladder Cancer | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 428 | 2025-02-01 | 2025-06-25 |
| A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC NDV01 intravesical controlled release formulation of gemcitabine and docetaxel - Non Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | Relmada Therapeutics, Inc. | 70 | 2024-08-01 | 2026-09-02 |
| A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer ZH9 - NMIBC, High Risk NMIBC | Phase 1 | Completed | Prokarium Ltd | 22 | 2024-01-08 | 2026-10-14 |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, Urologic Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 367 | 2023-12-14 | 2026-07-01 |
| Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) N803 plus Bacillus Calmette-Guerin (BCG) - Non Muscle Invasive Bladder Cancer | Active not recruiting | ImmunityBio, Inc. | 6 | 2023-08-17 | 2026-04-29 | |
| Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer | Completed | AstraZeneca | 400 | 2023-07-10 | 2025-04-11 | |
| The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection Urine biomarker -Guided without reTURBT - Non Muscle Invasive Bladder Cancer | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 428 | 2023-07-01 | 2024-03-01 |
| Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer Second TURBt - Bladder Cancer, Non Muscle Invasive Bladder Cancer | Completed | University of Trieste | 1300 | 2022-01-01 | 2024-01-12 | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer | Phase 2 | Completed | CG Oncology, Inc. | 35 | 2020-12-08 | 2024-09-25 |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 190 | 2020-10-27 | 2026-07-10 |
| Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer Bladder EpiCheck - Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Completed | Nucleix Ltd. | 168 | 2019-09-05 | 2023-09-07 |
Showing 20 of 29. Sign in to see all of them.
Non-Muscle Invasive Bladder Neoplasms (29) · Urinary Bladder Neoplasms (12) · Carcinoma in Situ (4) · Carcinoma, Transitional Cell (4) · Neoplasms (3) · Carcinoma (2) · Fanconi Syndrome (2) · Recurrence (2) · Urinary Bladder Diseases (2) · Urologic Neoplasms (2) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Urogenital Neoplasms (1) · Urologic Diseases (1)
Female Urogenital Diseases (29) · Female Urogenital Diseases and Pregnancy Complications (29) · Male Urogenital Diseases (29) · Neoplasms by Histologic Type (29) · Urogenital Diseases (29) · Neoplasms by Site (28) · Neoplasms, Glandular and Epithelial (28) · Urogenital Neoplasms (28) · Urologic Diseases (28) · Carcinoma (27) · Urinary Bladder Diseases (27) · Urologic Neoplasms (27) · Neoplasms (26) · Urinary Bladder Neoplasms (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
dodecyl maltoside (4) · Gemcitabine (3) · BCG Vaccine (2) · ALT-803 (1) · Celecoxib (1) · Docetaxel (1) · Imiquimod (1) · Mitomycin (1) · Polysorbates (1) · Prospective Studies (1) · Ty21a typhoid vaccine (1) · Watchful Waiting (1) · pembrolizumab (1) · toripalimab (1)
CG Oncology, Inc. (3) · The First Affiliated Hospital with Nanjing Medical University (2) · AC.TA. S.r.l. (1) · Ankara University (1) · Assiut University (1) · AstraZeneca (1) · Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari (1) · BLATAM (1) · Bladder Cancer Advocacy Network (1) · IRCCS San Raffaele (1) · ImmunityBio, Inc. (1) · Institut Claudius Regaud (1) · Lepu Biopharma Co., Ltd. (1) · Nucleix Ltd. (1) · Oslo University Hospital (1)
United States (8) · China (4) · Italy (4) · South Korea (3) · Canada (2) · Israel (2) · Argentina (1) · Australia (1) · Brazil (1) · France (1) · Japan (1) · Norway (1) · Switzerland (1) · Taiwan (1) · Turkey (Türkiye) (1)
Andreas Habberstad, MD, PhD (1) · Bobby Reddy, MD (1) · Boris Chertin (1) · Dongliang Xu (1) · Fernando Maluf, MD (1) · Francesco Montorsi, MD (1) · Gaetano Facchini, MD (1) · Hailong Hu, MD (1) · Ja Hyeon Ku (1) · Josefin-Beate Holz, MD (1) · Max Kates, MD (1) · Paolo Puppo, MD (1) · Vincenzo VP Pagliarulo, Medical Doctor (1)
PMID 20509796, PMID 22280855, PMID 28341495, PMID 36212980, PMID 38844794, PMID 42054609, PMID 42508433